2.1. The goal of this funding opportunity is to fund phase one (1), two (2), and/or three (3) clinical trials that are capable of being approved by the United States (U.S.) Food and Drug Administration (FDA) and authorized by the U.S. Drug Enforcement Administration (DEA), for evaluating the effects of whole mushroom psilocybin in the treatment of any of the following conditions, disorders, or illnesses: 2.1.1. Post-traumatic stress disorder. 2.1.2. Symptoms associated with long COVID-19. 2.1.3. Depression. 2.1.4. Anxiety disorders. 2.1.5. Symptoms associated with end-of-life distress. 2.1.6. Obsessive-compulsive disorder. 2.1.7. Substance abuse and addiction disorders. 2.1.8. Eating disorders. 2.1.9. Chronic pain. 2.1.10. Inflammatory disorders. 2.1.11. Autoimmune disorders. 2.1.12. Seizure disorders. 2.1.13. Other degenerative disorders. 2.2. The ABRC shall give priority to Applications that include randomized controlled clinical trials that study the treatment of post-traumatic stress disorder, symptoms associated with long-term COVID-19, depression, anxiety disorders, symptoms associated with end-of-life distress, obsessive-compulsive disorder, substance abuse and addiction disorders, eating disorders, chronic pain, inflammatory disorders, autoimmune disorders, seizure disorders, and other degenerative disorders. 2.3. The results of these projects are expected to accelerate promising research, which may improve the health and wellness of Arizonans. While ABRC’s strong emphasis is on funding basic and translational research projects, the ABRC continues to seek innovative projects that leverage Arizona’s resources and strengthen collaboration. A strong emphasis will be focused on applications that are multidisciplinary and employ collaborative approaches. Collaboration among investigators could include within an institution, across institutions, or across disciplines.
